At the news
? NEUTRALIMPACT 2/10 144 filed Aug 13, 2026 at 17:03 ET
Director Douglas Kerr filed a Form 144 notice of intent to sell 2,443 shares of Dyne Therapeutics common stock, with an estimated aggregate market value of approximately $64,203 based on the filing date. The shares were acquired through vesting of restricted stock units granted under the issuer's equity compensation plan. This is a routine, small-dollar sale relative to the company's $4.9B market cap and does not signal a change in business outlook or management confidence.
- Director Douglas Kerr filed Form 144 to sell 2,443 shares of Dyne Therapeutics common stock.
- Estimated aggregate market value of the proposed sale is approximately $64,203.
- Shares were acquired through vesting of restricted stock units (RSUs) granted under equity compensation plans on 08/12/2026 and 06/05/2026.
- The sale is to be executed through Stifel Nicolaus & Company Inc.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access